Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 2
1989 1
1990 2
1991 4
1992 2
1993 3
1994 3
1995 2
1996 7
1997 5
1998 4
1999 3
2000 6
2001 2
2002 7
2003 4
2004 6
2005 10
2006 14
2007 9
2008 8
2009 11
2010 13
2011 6
2012 9
2013 10
2014 17
2015 7
2016 12
2017 13
2018 8
2019 9
2020 16
2021 8
2022 6
2023 9
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

245 results

Results by year

Filters applied: . Clear all
Page 1
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study.
Siderowf A, Concha-Marambio L, Lafontant DE, Farris CM, Ma Y, Urenia PA, Nguyen H, Alcalay RN, Chahine LM, Foroud T, Galasko D, Kieburtz K, Merchant K, Mollenhauer B, Poston KL, Seibyl J, Simuni T, Tanner CM, Weintraub D, Videnovic A, Choi SH, Kurth R, Caspell-Garcia C, Coffey CS, Frasier M, Oliveira LMA, Hutten SJ, Sherer T, Marek K, Soto C; Parkinson's Progression Markers Initiative. Siderowf A, et al. Among authors: kieburtz k. Lancet Neurol. 2023 May;22(5):407-417. doi: 10.1016/S1474-4422(23)00109-6. Lancet Neurol. 2023. PMID: 37059509 Free PMC article.
Trichloroethylene: An Invisible Cause of Parkinson's Disease?
Dorsey ER, Zafar M, Lettenberger SE, Pawlik ME, Kinel D, Frissen M, Schneider RB, Kieburtz K, Tanner CM, De Miranda BR, Goldman SM, Bloem BR. Dorsey ER, et al. Among authors: kieburtz k. J Parkinsons Dis. 2023;13(2):203-218. doi: 10.3233/JPD-225047. J Parkinsons Dis. 2023. PMID: 36938742 Free PMC article. Review.
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research.
Simuni T, Chahine LM, Poston K, Brumm M, Buracchio T, Campbell M, Chowdhury S, Coffey C, Concha-Marambio L, Dam T, DiBiaso P, Foroud T, Frasier M, Gochanour C, Jennings D, Kieburtz K, Kopil CM, Merchant K, Mollenhauer B, Montine T, Nudelman K, Pagano G, Seibyl J, Sherer T, Singleton A, Stephenson D, Stern M, Soto C, Tanner CM, Tolosa E, Weintraub D, Xiao Y, Siderowf A, Dunn B, Marek K. Simuni T, et al. Among authors: kieburtz k. Lancet Neurol. 2024 Feb;23(2):178-190. doi: 10.1016/S1474-4422(23)00405-2. Lancet Neurol. 2024. PMID: 38267190 Review.
Levodopa and the progression of Parkinson's disease.
Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K; Parkinson Study Group. Fahn S, et al. Among authors: kieburtz k. N Engl J Med. 2004 Dec 9;351(24):2498-508. doi: 10.1056/NEJMoa033447. N Engl J Med. 2004. PMID: 15590952 Free article. Clinical Trial.
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R; Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab Study Group. Doody RS, et al. Among authors: kieburtz k. N Engl J Med. 2014 Jan 23;370(4):311-21. doi: 10.1056/NEJMoa1312889. N Engl J Med. 2014. PMID: 24450890 Free article. Clinical Trial.
Deep Phenotyping of Parkinson's Disease.
Dorsey ER, Omberg L, Waddell E, Adams JL, Adams R, Ali MR, Amodeo K, Arky A, Augustine EF, Dinesh K, Hoque ME, Glidden AM, Jensen-Roberts S, Kabelac Z, Katabi D, Kieburtz K, Kinel DR, Little MA, Lizarraga KJ, Myers T, Riggare S, Rosero SZ, Saria S, Schifitto G, Schneider RB, Sharma G, Shoulson I, Stevenson EA, Tarolli CG, Luo J, McDermott MP. Dorsey ER, et al. Among authors: kieburtz k. J Parkinsons Dis. 2020;10(3):855-873. doi: 10.3233/JPD-202006. J Parkinsons Dis. 2020. PMID: 32444562 Free PMC article. Review.
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.
Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A; LCIG Horizon Study Group. Olanow CW, et al. Among authors: kieburtz k. Lancet Neurol. 2014 Feb;13(2):141-9. doi: 10.1016/S1474-4422(13)70293-X. Epub 2013 Dec 20. Lancet Neurol. 2014. PMID: 24361112 Free PMC article. Clinical Trial.
Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial.
NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee; Wall M, McDermott MP, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, Katz DM, Keltner JL, Schron EB, Kupersmith MJ. NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee, et al. Among authors: kieburtz kd. JAMA. 2014 Apr 23-30;311(16):1641-51. doi: 10.1001/jama.2014.3312. JAMA. 2014. PMID: 24756514 Free PMC article. Clinical Trial.
Moving Parkinson care to the home.
Dorsey ER, Vlaanderen FP, Engelen LJ, Kieburtz K, Zhu W, Biglan KM, Faber MJ, Bloem BR. Dorsey ER, et al. Among authors: kieburtz k. Mov Disord. 2016 Sep;31(9):1258-62. doi: 10.1002/mds.26744. Epub 2016 Aug 8. Mov Disord. 2016. PMID: 27501323 Free PMC article. Review.
245 results